Zobrazeno 1 - 10
of 411
pro vyhledávání: '"Irene M. Ghobrial"'
Autor:
Graham A. Colditz, Brenda M. Birmann, Irene M. Ghobrial, Timothy R. Rebbeck, Dong-Hoon Lee, Catherine R. Marinac, Bernard Rosner, Mark Bustoros
Publikováno v:
Cancer Epidemiology, Biomarkers & Prevention. 31:479-485
Background: Inflammation is important in multiple myeloma pathogenesis, and regular aspirin use has been shown to confer a reduced risk of multiple myeloma. The influence of aspirin on survival after multiple myeloma diagnosis is unknown. Methods: We
Autor:
Nicholas Tsakmaklis, Aldo M. Roccaro, Timothy P White, Christopher J. Patterson, Guang Yang, Antonio Sacco, Xia Liu, Yang Cao, Zachary R. Hunter, Shayna Sarosiek, Carly Leventoff, Irene M. Ghobrial, Manit Munshi, Jorge J. Castillo, Lian Xu, Steven P. Treon, Catherine A Flynn, Kirsten Meid, Andrew R. Branagan, Amanda Kofides, Maria Luisa Guerrera, Maria Demos
Publikováno v:
Blood
MYD88 and CXCR4 mutations are common in Waldenström macroglobulinemia (WM). Mutated CXCR4 (CXCR4Mut) impacts BTK-inhibitor response. We conducted a phase 1 trial of the CXCR4-antagonist ulocuplumab with ibrutinib in this first-ever study to target C
Autor:
Robert A. Redd, Matthew Leventhal, Irene M. Ghobrial, Nikhil C. Munshi, Christopher J. Gibson, Jerome Ritz, Amin Nassar, Chip Stewart, Jihye Park, Romanos Sklavenitis-Pistofidis, Marzia Capelletti, Cody J. Boehner, David P. Steensma, Saud H. AlDubayan, Daniel Auclair, Lorenzo Trippa, Muhieddine M. Itani, Benjamin L. Ebert, Kalvis Hornburg, Shaadi Mehr, Mark Bustoros, Robert L. Schlossman, Henry Dumke, Jacob P. Laubach, Adam S. Sperling, Gad Getz, Salomon Manier, Paul G. Richardson, Eliezer M. Van Allen, Tarek H. Mouhieddine, Sabrin Tahri, Kenneth C. Anderson, Robert J. Soiffer, Daisy Huynh, Donna Neuberg, Brendan Reardon, Chia Jen Liu, Jonathan J Keats
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-9 (2020)
Nature Communications
Nature Communications, Nature Publishing Group, 2020, 11 (1), pp.2996. ⟨10.1038/s41467-020-16805-5⟩
Nature Communications, 2020, 11 (1), pp.2996. ⟨10.1038/s41467-020-16805-5⟩
Nature Communications
Nature Communications, Nature Publishing Group, 2020, 11 (1), pp.2996. ⟨10.1038/s41467-020-16805-5⟩
Nature Communications, 2020, 11 (1), pp.2996. ⟨10.1038/s41467-020-16805-5⟩
Multiple myeloma (MM) is a plasma-cell neoplasm that is treated with high-dose chemotherapy, autologous stem cell transplant (ASCT) and long-term immunomodulatory drug (IMiD) maintenance. The presence of somatic mutations in the peripheral blood is t
Autor:
Justin Cha, Cody J. Boehner, Nikhil C. Munshi, Romanos Sklavenitis-Pistofidis, Kwee Yong, Chip Stewart, Karma Salem, Eliezer M. Van Allen, Jihye Park, Yu-Tzu Tai, Andrew Dunford, Shankara Anand, Lorenzo Trippa, Amaro Taylor-Weiner, Jacob P. Laubach, Mark Bustoros, Benny Zhitomirsky, Robert A. Redd, Selina J Chavda, Irene M. Ghobrial, Shaji Kumar, Paul G. Richardson, Kenneth C. Anderson, François Aguet, Tarek H. Mouhieddine, P. Leif Bergsagel, Gad Getz, Mahshid Rahmat, Tineke Casneuf, Meletios A. Dimopoulos, Liudmila Elagina, Carl Jannes Neuse, Salomon Manier, Elizabeth A. Morgan, Ignaty Leshchiner, Efstathis Kastritis
Publikováno v:
J Clin Oncol
PURPOSE Smoldering multiple myeloma (SMM) is a precursor condition of multiple myeloma (MM) with a 10% annual risk of progression. Various prognostic models exist for risk stratification; however, those are based on solely clinical metrics. The disco
Autor:
Christopher A. Haiman, Laura D. Kubzansky, Brianna M. Leonardo, Walter C. Willett, Lynn Rosenberg, Alpa V. Patel, Denis Nash, Loic Le Marchand, Shepherd H. Schurman, A. Heather Eliassen, Laura Beane-Freeman, Jae H. Kang, Long H. Nguyen, Lynne R. Wilkens, Jacqueline J. Flynn, Mingyang Song, James V. Lacey, Irene M. Ghobrial, Annie Cowan, Marina V. Magicheva-Gupta, Tim D. Spector, Paul W. Franks, Dale P. Sandler, Roger L. Milne, Maria Elena Martinez, Sohee Kwon, Raaj S. Mehta, Lorelei A. Mucci, Jane C. Figueiredo, Catherine R. Marinac, Jaime E. Hart, Zahra S. Fatehi, Karestan C. Koenen, Amit Joshi, Jorge E. Chavarro, Sebastien Ourselin, Brenda Kirpach, Christine M. Albert, Shreela V. Sharma, Meir J. Stampfer, Wenjie Ma, Daniel Sikavi, Sandra Deming-Halverson, Andrew T. Chan, John S. Brownstein, Janet E. Hall, Bijal A. Balasubramanian, Anusila Deka, Janet W. Rich-Edwards, Chuan-Guo Guo, Claire J. Steves, Jonathan Wolf, Julie R. Palmer, Fiona Bruinsma, Gabriella Andreotti, Michael E. Ernst, Anne M. Murray, Chun-Han Lo, Christopher D. Gardner, David A. Drew
Publikováno v:
Cancer Epidemiology, Biomarkers & Prevention
The rapid pace of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; COVID-19) pandemic presents challenges to the real-time collection of population-scale data to inform near-term public health needs as well as future investigations. W
Autor:
Jorge J. Castillo, Kirsten Meid, Maria Luisa Guerrera, Guang Yang, Irene M. Ghobrial, Steven P. Treon, Jacob D. Soumerai, Alan P Skarbnik
Publikováno v:
Blood. 135:1912-1915
Treon et al provide early clinical data supporting a theoretical rationale for continuing ibrutinib in patients receiving the drug during COVID-19 illness.
Autor:
Irene M. Ghobrial, Oliver Lomas
Publikováno v:
American Society of Clinical Oncology Educational Book. :314-319
Forty years ago this year, smoldering multiple myeloma was defined as a clinical entity that identifies a group of patients with a substantial burden of disease but with a relatively indolent natural history compared with symptomatic disease. Since t
Autor:
Irene M. Ghobrial, Michael Andreeff, Dominique Bonnet, Daniela S. Krause, Simón Méndez-Ferrer, David P. Steensma, John G. Gribben, Robert P. Hasserjian
Publikováno v:
Nature Reviews Cancer
Nat Rev Cancer
Nat Rev Cancer
Haematological malignancies were previously thought to be driven solely by genetic or epigenetic lesions within haematopoietic cells. However, the niches which maintain and regulate daily production of blood and immune cells are now increasingly bein
Autor:
Catherine R. Marinac, Brenda M. Birmann, Jenny Soiffer, Irene M. Ghobrial, Timothy R. Rebbeck
Publikováno v:
Blood Cancer Journal, Vol 10, Iss 2, Pp 1-8 (2020)
Multiple myeloma (MM) is a fatal plasma cell dyscrasia with a median overall survival of 5 to 10 years. MM progresses from the more common but often subclinical precursor states of monoclonal gammopathy of undetermined significance (MGUS), and smolde
Autor:
Peter Sabbatini, Stacey Chuma, Rachid Baz, Jacob P. Laubach, Robert A. Redd, Alexandra Savell, Raymond P. Perez, Pamela S. Becker, Patrick Henrick, Kenneth C. Anderson, Oksana Zavidij, Chia Jen Liu, Kalvis Hornburg, Romanos Sklavenitis-Pistofidis, Michael Robbins, Kaitlen Reyes, Paul G. Richardson, Irene M. Ghobrial
Publikováno v:
Clinical Cancer Research. 26:344-353
Purpose: Ulocuplumab (BMS-936564) is a first-in-class fully human IgG4 monoclonal anti-CXCR4 antibody that inhibits the binding of CXCR4 to CXCL12. Patients and Methods: This phase Ib/II study aimed to determine the safety and tolerability of ulocupl